The FDA has approved Juvéderm Voluma XC (Allergan), the first injectable filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. The approval is based on a pivotal clinical trial in the US and Canada demonstrating that Juvéderm Voluma XC was both a safe and effective treatment compared to the control group. Made with Allergan's proprietary VYCROSS technology, an advanced manufacturing process that results in a smooth gel that flows easily and consistently, Juvéderm Voluma XC helps create a more youthful appearance to the face and provides natural-looking results that last up to two years, according to the company. Additionally, Juvéderm Voluma XC contains a small amount of lidocaine which helps to numb the treatment area during the injection procedure. For more information on the Juvéderm family of products, visit www.juvederm.com.